What's New
| FAQ Library Does aspirin's anti-inflammatory properties lower melanoma risk? Jeffrey Weber, MD, PhD Why is BRAF V600E mutation testing required prior to vemurafenib therapy? Jeffrey Weber, MD, PhD |
| Reducing the Risk of Oncologic Emergencies: Assessment and Treatment of Severe Neutropenia Rajni Sinha, MD, MRCP; R. Donald Harvey III, PharmD, FCCP, BCOP |
| ASH 2012 Video-based Annual Meeting Highlights in Hematological Malignancies Alan K. Burnett, MD; Craig Moskowitz, MD; Susan M. O'Brien, MD; Neil P. Shah, MD, PhD; Andrew Zelenetz, MD, PhD |
| ASH 2012 Text-based Annual Meeting Highlights: Oncology Experts Highlight Leukemia and Lymphoma Clinical Trials Bret Fulton, RPh - Medical Writer |